Pheng Leng Hong, Dumont Yvan, Fournier Alain, Chabot Jean-Guy, Beaudet Alain, Quirion Rémi
Douglas Hospital Research Center and Department of Psychiatry, Faculty of Medicine, McGill University, Verdun, Québec, Canada H4H 1R3.
Br J Pharmacol. 2003 Jun;139(4):695-704. doi: 10.1038/sj.bjp.0705306.
1 Neuropeptide Y Y(1) receptors are known to internalize following the binding of agonists. In the present study, a pseudopeptide Y(1) receptor antagonist, homodimeric Ile-Glu-Pro-Dpr-Tyr-Arg-Leu-Arg-Tyr-CONH(2) (GR231118), also induced Y(1) receptor internalization in human embryonic kidney (HEK293) cells. 2 We demonstrated first that both specifically bound radiolabeled antagonist ([(125)I]GR231118) and agonist ([(125)I][Leu(31), Pro(34)]PYY) underwent receptor-mediated sequestration/internalization in transfected HEK293 cells. 3 Agonist-induced Y(1) receptor internalization was dependent on clathrin-coated pits and was regulated in part by Gi/o-protein activation as revealed by pertussin toxin sensitivity. In contrast, antagonist-induced sequestration of Y(1) receptors was partly dependent on clathrin-coated pits, but independent from Gi/o-protein activation. 4 Exposure to high concentrations of agonist or antagonist caused a 50 and 75% loss of cell surface binding, respectively. The loss caused by the agonist rapidly recovered. This phenomenon was blocked by monensin, an inhibitor of endosome acidification, suggesting that cell surface receptor recovery is due to recycling. In contrast to the agonist, GR231118 induced a long-lasting sequestration of Y(1) receptors in HEK293 cells. 5 Immunofluorescence labeling indicated that following 40 min of incubation with either the agonist or the antagonist, Y(1) receptors followed markedly different intercellular trafficking pathways. 6 Taken together, these findings provided evidence that a pseudopeptide Y(1) receptor antagonist can induce long-lasting disappearance of cell surface receptors through a pathway distinct from the classical endocytic/recycling pathway followed by stimulation with an agonist.
1 已知神经肽Y Y(1)受体在激动剂结合后会发生内化。在本研究中,一种假肽Y(1)受体拮抗剂,同二聚体异亮氨酸-谷氨酸-脯氨酸-二氢脯氨酸-酪氨酸-精氨酸-亮氨酸-精氨酸-酪氨酸-羧基酰胺(2)(GR231118),也能诱导人胚肾(HEK293)细胞中的Y(1)受体内化。2 我们首先证明,特异性结合的放射性标记拮抗剂([(125)I]GR231118)和激动剂([(125)I][亮氨酸(31),脯氨酸(34)]PYY)在转染的HEK293细胞中都经历了受体介导的隔离/内化。3 激动剂诱导的Y(1)受体内化依赖于网格蛋白包被小窝,并且如百日咳毒素敏感性所揭示的,部分受Gi/o蛋白激活调节。相比之下,拮抗剂诱导的Y(1)受体隔离部分依赖于网格蛋白包被小窝,但独立于Gi/o蛋白激活。4 暴露于高浓度的激动剂或拮抗剂分别导致细胞表面结合丧失50%和75%。激动剂引起的丧失迅速恢复。这种现象被莫能菌素阻断,莫能菌素是一种内体酸化抑制剂,表明细胞表面受体的恢复是由于再循环。与激动剂不同,GR231118在HEK293细胞中诱导Y(1)受体的长期隔离。5 免疫荧光标记表明,在用激动剂或拮抗剂孵育40分钟后,Y(1)受体遵循明显不同的细胞间运输途径。6 综上所述,这些发现提供了证据,表明一种假肽Y(1)受体拮抗剂可以通过一条不同于激动剂刺激后遵循的经典内吞/再循环途径的途径,诱导细胞表面受体的长期消失。